ALGS - Aligos Therapeutics Inc Stock Price, Fair Value and News

0.54USD0.00 (0.00%)Market Closed

Market Summary

USD0.540.00

Market Closed

0.00%

ALGS Stock Price

View Fullscreen

ALGS RSI Chart

ALGS Valuation

Market Cap

40.9M

Price/Earnings (Trailing)

-0.41

Price/Sales (Trailing)

4.47

EV/EBITDA

-0.17

Price/Free Cashflow

-0.51

ALGS Price/Sales (Trailing)

ALGS Profitability

EBT Margin

-1079.74%

Return on Equity

-166.54%

Return on Assets

-77.86%

Free Cashflow Yield

-194.21%

ALGS Fundamentals

ALGS Revenue

Revenue (TTM)

9.2M

Rev. Growth (Yr)

-82.28%

Rev. Growth (Qtr)

-65.46%

ALGS Earnings

Earnings (TTM)

-99.6M

Earnings Growth (Yr)

-51.88%

Earnings Growth (Qtr)

-24.99%

Breaking Down ALGS Revenue

Last 7 days

12.2%

Last 30 days

37.5%

Last 90 days

-29.5%

Trailing 12 Months

-39.2%

How does ALGS drawdown profile look like?

ALGS Financial Health

Current Ratio

6.25

ALGS Investor Care

Shares Dilution (1Y)

76.34%

Diluted EPS (TTM)

-1.04

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	9.2M	0	0	0
2023	12.8M	11.6M	10.5M	9.3M
2022	6.0M	8.2M	10.7M	13.9M
2021	0	0	0	4.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About Aligos Therapeutics Inc

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-097558, which is in Phase I clinical trial for the treatment of coronavirus; and ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB). The company also develops ALG-055009, a small molecule THR-ÃƒÆ’Ã…Â¸ agonist that is in the Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). In addition, it develops siRNA drug candidate, ALG-125755, which is in Phase I clinical trial for the treatment of CHB. Aligos Therapeutics, Inc. has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH, as well as a research collaboration and development agreement with Xiamen Amoytop Biotech Co., Ltd. to research and develop oligonucleotide compounds for the treatment of liver diseases.. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

CEO	Dr. Lawrence M. Blatt MBA, Ph.D.
WEBSITE	aligos.com
INDUSTRY	Biotechnology
EMPLOYEES	68

Aligos Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Aligos Therapeutics Inc? What does ALGS stand for in stocks?

ALGS is the stock ticker symbol of Aligos Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aligos Therapeutics Inc (ALGS)?

As of Thu Jul 25 2024, market cap of Aligos Therapeutics Inc is 40.86 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALGS stock?

You can check ALGS's fair value in chart for subscribers.

Is Aligos Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ALGS is over valued or under valued. Whether Aligos Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aligos Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALGS.

What is Aligos Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, ALGS's PE ratio (Price to Earnings) is -0.41 and Price to Sales (PS) ratio is 4.47. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALGS PE ratio will change depending on the future growth rate expectations of investors.